Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib plus S-1 after NG regimen failure in metastatic pancreatic cancer
ChiCTR2100053712Phase 4Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Dec 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donafenib and tegafur + gimeracil + oteracil in pancreatic cancer (PC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: overall survival. Started Dec 2021; status: recruiting.
02
Drugs
donafenibtegafur + gimeracil + oteracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2100053712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053712.